Medicenna Therapeutics Corp. (TSE:MDNA - Get Free Report) shares were down 3.8% during mid-day trading on Monday . The company traded as low as C$1.17 and last traded at C$1.27. Approximately 47,723 shares changed hands during trading, a decline of 27% from the average daily volume of 65,261 shares. The stock had previously closed at C$1.32.
Medicenna Therapeutics Stock Up 0.8 %
The firm has a market capitalization of C$97.07 million, a price-to-earnings ratio of -3.34 and a beta of 1.21. The business's fifty day moving average price is C$1.56 and its 200 day moving average price is C$1.92. The company has a current ratio of 2.51, a quick ratio of 4.65 and a debt-to-equity ratio of 0.06.
Insider Activity
In related news, Senior Officer David Hyman bought 20,000 shares of the company's stock in a transaction dated Thursday, January 9th. The shares were acquired at an average price of C$1.45 per share, with a total value of C$29,000.00. Corporate insiders own 22.57% of the company's stock.
About Medicenna Therapeutics
(
Get Free Report)
Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.
Recommended Stories
Before you consider Medicenna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medicenna Therapeutics wasn't on the list.
While Medicenna Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
